VolleyAGPC: Alpha-GPC and Physical and Cognitive Performances in Volleyball Players.

Sponsor
Université de Montréal (Other)
Overall Status
Completed
CT.gov ID
NCT02886130
Collaborator
(none)
28
1
2
3.7
7.5

Study Details

Study Description

Brief Summary

In order to attain the elite level on the national scene, volleyball players need several attributes. In addition to mastering technical and tactical skills, great jumping ability is another important asset. Maximal power output needed to achieve height during a jump necessitates coordinated neuromuscular recruitment and muscle mass among others. Interestingly, there are claims that alpha-glycerylphosphorylcholine (A-GPC) increases acetylcholine synthesis and enhances exercise-induced increases in plasma growth hormone concentrations, two factors that could theoretically be associated neuromuscular transmission and muscle mass.

However, until now only a few studies have investigated the role of A-GPC in human exercise performance. Published results were mixed. One recent study showed that isometric peak force was slightly but significantly increased when subjects had ingested a daily dose of 600 mg of A-GPC over a period of 6 days (Bellar et al., JISSN, 2015).

The objective of our study is to evaluate the longer-term effects (4 weeks) using a higher dose (1000 mg/day) of A-GPC on jumping capabilities in elite male and female volleyball players.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Placebo
  • Dietary Supplement: Experimental
N/A

Detailed Description

Our study design will be a placebo controlled, randomized, double-blind, crossover study. Varsity male and female volleyball players (n=28) will each be asked to participate in both arms of the study, i.e. placebo and A-GPC (1000 mg/kg/day). The duration of each arm of the study will be 4 weeks separated by a 7-day washout period. The order of treatment (placebo or A-GPC) will be determined randomly. Athletes will be asked to maintain their training load during the duration of the experiment.

Study Design

Study Type:
Interventional
Actual Enrollment :
28 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Basic Science
Official Title:
Effects of Alpha-glycerylphosphorylcholine on Physical and Cognitive Performances in Varsity Volleyball Players
Actual Study Start Date :
Aug 29, 2016
Actual Primary Completion Date :
Dec 20, 2016
Actual Study Completion Date :
Dec 20, 2016

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Placebo

Maltodextrin tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration

Dietary Supplement: Placebo
Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
Other Names:
  • Maltodextrin
  • Control
  • Experimental: Alpha-GPC

    Alpha-GPC tablets (4x per day) 2 x 250 mg in the morning, 2 x 250 mg 60 min before workout, 4 weeks duration

    Dietary Supplement: Experimental
    Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
    Other Names:
  • Alpha-gpc
  • Alpha-glycerylphosphorylcholine
  • Alpha-gpc supplementation
  • A-GPC
  • Outcome Measures

    Primary Outcome Measures

    1. Change in countermovement jump performance at 4 weeks [Assessments at week 0 and at week 4 of supplementation or placebo]

      Jump height is calculated using two forces plates which measures the time the feet are off the platform. The athlete stands upright with weight evenly distributed over both feet. Hands are placed on the hips, and stay there throughout the test. When all is ready, the athlete squats down until the knees are bent at 90 degrees, then immediately jumps vertically as high as possible, landing back on the platform on both feet at the same time. Allow a good rest between trials. The take-off must be from both feet, with no initial steps or shuffling. They must also not pause at the base of the squat.

    Secondary Outcome Measures

    1. Change in vertical jump - run up at 4 weeks [Assessments at week 0 and at week 4 of supplementation or placebo]

      Record the standing height of the subject by getting then to stand directly below the apparatus with both feet on tip-toes, and then stretch up one arm and reach as high as possible. The subject then stands the appropriate distance from the base of the apparatus (about 15 feet), and when ready take 3 or so steps before leaping off up off both legs as high as possible, using the arms to assist in projecting the body upwards. The subject should aim to take off just short of the apparatus, so that at the peak of the jump they are directly under it.

    2. Executive function [After 4 weeks of supplementation or placebo]

      "Task switching" is a useful tool to investigate executive functions in humans. This task allows investigation of the ability to maintain, select and switch among task sets.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    19 Years to 30 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Be a competitive varsity volleyball player
    Exclusion Criteria:
    • Regular consumption of alpha-GPC within the last 4 months

    • Receiving drug treatment except 1) contraception (pill), and 2) treatment against asthma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 CEPSUM (Centre d'éducation physique et des sports de l'université de Montréal) Montreal Quebec Canada H3C3J7

    Sponsors and Collaborators

    • Université de Montréal

    Investigators

    • Principal Investigator: Samuel St-Arnaud, B.Sc, Université de Montréal
    • Study Director: Raynald Bergeron, Ph.D, Université de Montréal
    • Study Director: Jonathan Tremblay, Ph.D, Université de Montréal

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Raynald Bergeron, Associate professor, Université de Montréal
    ClinicalTrials.gov Identifier:
    NCT02886130
    Other Study ID Numbers:
    • Montreal
    First Posted:
    Sep 1, 2016
    Last Update Posted:
    Apr 21, 2017
    Last Verified:
    Apr 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by Raynald Bergeron, Associate professor, Université de Montréal

    Study Results

    No Results Posted as of Apr 21, 2017